Fish-eye disease: Structural and in vivo metabolic abnormalities of high-density lipoproteins

Metabolism: Clinical and Experimental

Volumn 46, Issue 5, 1997, Pages 474-483

  Elkhalil, Latifa ^b   Majd, Zouher ^b   Bakir, Redouane ^b   Perez Mendez, Oscar ^b   Castro, Graciela ^b   Poulain, Philippe ^b   Lacroix, Brigitte ^b   Duhal, Nathalie ^b   Fruchart, Jean Charles ^b   Luc, Gérald ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CASE REPORT; CORNEA OPACITY; FEMALE; GENETIC DISORDER; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

EID: 2042441728     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90180-3     Document Type: Article

References (65)

1. Carlson LA, Philipson B: Fish eye disease: A new familial condition with massive corneal opacities and dyslipoproteinemia. Lancet 2:1373-1377, 1979
2. Carlson LA: A further case of fish eye disease. Lancet 2:921-923, 1979
3. Carlson LA: Fish eye disease: A new familial condition with massive corneal opacities and dyslipoproteinemia. Eur J Clin Invest 12:41-53, 1982
4. Carlson LA, Holmquist L: Paradoxical esterification of plasma cholesterol in fish eye disease. Acta Med Scand 217:491-499, 1985
5. Breslow JL: Familial disorders of high density lipoprotein metabolism, in Scriver CR, Beaudet AL, Sly WS, et al (eds): The Metabolic Basis of Inherited Disease (ed 6). New York, NY, McGraw-Hill, 1989, pp 1251-1266
6. Carlson LA, Holmquist L: Evidence for the presence in human plasma of lecithin:cholesterol acyltransferase activity (β-LCAT) specifically esterifying free cholesterol of combined pre-β- and β-lipoproteins: Studies of fish eye disease patients and control subjects. Acta Med Scand 218:197-205, 1985
7. Duverger N, Klein HG, Luc G, et al: Identification of a novel mutation in the LCAT gene resulting in fish eye disease with α-LCAT activity. Circulation 88:I-423, 1993 (abstr 2274)
8. Klein HG, Lohse P, Pritchard PH, et al: Two different allelic mutations in the lecithin:cholesterol acyltransferase gene associated with the fish eye syndrome. J Clin Invest 89:499-506, 1992
9. Klein HG, Santamarini-Fojo S, Duverger N, et al: Fish eye disease: A molecular defect on the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal α-LCAT specific activity. J Clin Invest 92:479-485, 1993
10. Skretting G, Prydz H: An amino acid exchange in exon 1 of the human lecithin:cholesterol acyl transferase (LCAT) gene is associated with fish eye disease. Biochem Biophys Res Commun 182:583-587, 1992
11. Funke H, Von Eckardstein A, Pritchard PH, et al: A molecular defect causing fish eye disease: An amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci USA 88:4855-4859, 1991
12. Kuivenhoven JA, Stalenhoef AFH, Hill JS, et al: Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscler Thromb Vasc Biol 16:294-303, 1996
13. Castelli WP, Doyle JT, Gordon T, et al: HDL cholesterol and other lipids in coronary heart disease: The Cooperative Lipoprotein Phenotyping Study. Circulation 55:767-772, 1977
14. Miller GJ, Miller NE: Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1:16-19, 1975
15. Nikkilä EA: Serum high-density lipoprotein and coronary heart disease. Lancet 2:320-323, 1976
16. Avogaro P, Bittolo Bon G, Cazzolato G, et al: Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1:901-903, 1979
17. Fager G, Wiklung O, Olofsson SO: Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factor: Apolipoprotein A-I levels in male survivors of myocardial infarction. Atherosclerosis 36:67-74, 1980
18. Parra HJ, Arveiler D, Evans AE, et al: A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 12:701-707, 1992
19. Franceschini G, Sirtori CR, Cadurso A, et al: AI Milano apoprotein: Decreased high density lipoprotein levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 66:892-900, 1980
20. Rader DJ, Ikewaki K, Duverger N, et al: Very low high-density lipoproteins without coronary atherosclerosis. Lancet 342:1455-1458, 1993
21. Serfaty Lacrosniere C, Civeira F, Lanzberg A, et al: Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 107:85-98, 1994
22. Parra HJ, Mezdour H, Ghalim N, et al: Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 36:1431-1435, 1990
23. Menzel HJ, Utermann G: Apolipoprotein E phenotyping from serum Western blotting. Electrophoresis 12:120-125, 1988
24. Fruchart JC, Fievet C, Puchois P: Apolipoproteins, in Bergmeyer HU (ed): Methods in Enzymatic Analysis. Weinheim, Germany, Verlag Chemie, 1985, pp 126-138
25. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
26. Towbin H, Staehelin T, Gordon T: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354, 1979
27. Chen C, Albers JJ: Characterization of proteoliposomes containing apoprotein A-I: A new substrate for the measurement of lecithin: cholesterol acyltransferase activity. J Lipid Res 23:680-691, 1982
28. de la Llera Moya M, Atger V, Paul JL, et al: A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb 14:1056-1065, 1994
29. Cobelli C, Toffolo G, Foster DM: Tracer to tracee ratio for analysis of stable tracer data: Link with radioactive kinetic formalism. Am J Physiol 262:E968-E975, 1992
30. Berman M, Weiss M: SAAM Manual. Bethesda, MD, National Institutes of Health, 1978
31. Reeds PJ, Hachey DL, Patterson BW, et al: VLDL apolipoprotein B-100, a potential indicator of the isotopic labeling of the hepatic protein synthetic precursor pool in humans: Studies with multiple stable isotopically labeled amino acids. J Nutr 122:457-466, 1992
32. Lee DM: Isolation and characterization of low density lipoproteins. New York, NY, Plenum, 1976, pp 3-45
33. Weisgraber KH, Mahley RW: Apoprotein (E-AII) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in high density lipoprotein subfractions. J Biol Chem 253:6281-6288, 1978
34. Assmann G, Von Eckardstein A, Funke H: Lecithin:cholesterol acyltransferase deficiency and fish-eye disease. Curr Opin Lipidol 2:110-117, 1991
35. Frohlich JJ, Hoag G, McLeod R, et al: Hypoalphalipoproteinemia resembling fish eye disease. Acta Med Scand 221:291-298, 1987
36. Kastelein JJP, Pritchard PH, Erkelens DW, et al: Familial high-density lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent. J Intern Med 231:413-419, 1992
37. Cryer DR, Matsushima T, March JB, et al: Direct measurement of apolipoprotein B synthesis in human very low density lipoprotein using stable isotopes and mass spectrometry. J Lipid Res 27:508-516, 1986
38. Ikewaki K, Rader DJ, Sakamoto T, et al: Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 92:1650-1658, 1993
39. Ikewaki K, Rader DJ, Schaefer JR, et al: Evaluation of apo A-I kinetics in humans using simultaneous stable isotope and exogenous radiotracer methods. J Lipid Res 34:2207-2215, 1993
40. Cohn JS, Wagner DA, Cohn SD, et al: Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 85:804-811, 1990
41. Emmerich J, Verges B, Tauveron I, et al: Familial HDL deficiency due to marked hypercatabolism of normal apoA-I. Arterioscler Thromb 13:1299-1306, 1993
42. Ikewaki K, Zech LA, Brewer HB, et al: ApoA-II kinetics in humans using endogenous labeling with stable isotopes: Slower turnover of apoA-II compared with the exogenous radiotracer method. J Lipid Res 37:399-407, 1996
43. Rader DJ, Ikewaki K, Duverger N, et al: Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 93:321-330, 1994
44. Brinton EA, Eisenberg S, Breslow JL: Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14:707-720, 1994
45. Fidge N, Nestel P, Ishikawa T, et al: Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. Metabolism 29:643-653, 1980
46. Schaefer EJ, Zech LA, Jenkins LL, et al: Human apolipoprotein A-I and A-II metabolism. J Lipid Res 23:850-862, 1982
47. Brinton EA, Eisenberg S, Breslow JL: Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest 84:262-269, 1989
48. Vega GL, Grundy SM: Metabolism of Apolipoprotein A-I and A-II in Man: Methods, Kinetic Models and Turnover Rates. London, UK, Academic, 1982, pp 397-407
49. Schaefer EJ, Ordovas JM: Metabolism of apolipoproteins A-I, A-II, and A-IV. Methods Enzymol 129:420-443, 1986
50. Kuivenhoven JA, Voorst EJGMVT, Wiebusch H, et al: A unique genetic and biochemical presentation of fish-eye disease. J Clin Invest 96:2783-2791, 1995
51. Brinton EA, Eisenberg S, Breslow JL: Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 87:536-544, 1991
52. Forte TM, Carlson LA: Electron microscopic structure of serum lipoprotein from patients with fish eye disease. Arteriosclerosis 4:130-137, 1984
53. Blanche PJ, Gong E, Forte TM, et al: Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 665:408-419, 1981
54. Horowitz BS, Goldberg IJ, Merab J, et al: Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91:1743-1752, 1993
55. Barbaras R, Puchois P, Fruchart J, et al: Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun 142:63-69, 1987
56. Kodama T, Akanuma Y, Okazaki M, et al: Abnormalities in plasma lipoprotein in familial partial lecithin:cholesterol acyltransferase deficiency. Biochim Biophys Acta 752:407-415, 1983
57. Sakuma M, Akanuma Y, Kodama T, et al: Familial plasma lecithin:cholesterol acyltransferase deficiency. Acta Med Scand 212:225-232, 1982
58. Soutar A, Knight BL, Myant NB: The characterization of lipoproteins in the high density fraction obtained from patients with familial lecithin:cholesterol acyltransferase deficiency and their interaction with cultured human fibroblasts. J Lipid Res 23:380-390, 1982
59. Ghiselli G, Krishnan S, Beigel Y, et al: Plasma metabolism of apolipoprotein A-IV in humans. J Lipid Res 27:813-827, 1986
60. Gregg RE, Zech LA, Schaefer EJ, et al: Apolipoprotein E metabolism in normolipoproteinemic human subjects. J Lipid Res 25:1167-1176, 1984
61. Innerarity TL, Mahley RW, Weisgraber KH, et al: Apolipoprotein (E-AII) complex of human plasma lipoprotein. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E-AII). J Biol Chem 253:6289-6295, 1978
62. Ikewaki K, Zech LA, Kindt M, et al: Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-LA-II in normolipidemic humans. Arterioscler Thromb Vasc Biol 15:306-312, 1995
63. Yamashita S, Sprecher DL, Sakai N, et al: Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest 86:688-695, 1990
64. Ohta T, Nakamura R, Takata K, et al: Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J Lipid Res 36:696-704, 1995
65. Huang YD, Voneckardstein A, Wu SL, et al: Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 15:1412-1418, 1995